miR-155 augments CD8+ T-cell antitumor activity in lymphoreplete hosts by enhancing responsiveness to homeostatic γc cytokines

被引:81
|
作者
Ji, Yun [1 ]
Wrzesinski, Claudia [2 ]
Yu, Zhiya [2 ]
Hu, Jinhui [1 ]
Gautam, Sanjivan [1 ]
Hawk, Nga V. [1 ]
Telford, William G. [1 ]
Palmer, Douglas C. [2 ]
Franco, Zulmarie [2 ]
Sukumar, Madhusudhanan [2 ]
Roychoudhuri, Rahul [2 ]
Clever, David [2 ]
Klebanoff, Christopher A. [2 ]
Surh, Charles D. [3 ]
Waldmann, Thomas A. [4 ]
Restifo, Nicholas P. [2 ]
Gattinoni, Luca [1 ]
机构
[1] NCI, Expt Transplantat & Immunol Branch, Ctr Canc Res, NIH, Bethesda, MD 20892 USA
[2] NCI, Surg Branch, Ctr Canc Res, NIH, Bethesda, MD 20892 USA
[3] Acad Immunol & Microbiol, Inst Basic Sci, Pohang 790784, South Korea
[4] NCI, Lymphoid Malignancies Branch, Ctr Canc Res, NIH, Bethesda, MD 20892 USA
基金
美国国家卫生研究院;
关键词
microRNA-155; adoptive immunotherapy; lymphodepletion; homeostatic cytokines; INCREASED INTENSITY LYMPHODEPLETION; METASTATIC MELANOMA; ADOPTIVE IMMUNOTHERAPY; IMMUNE-SYSTEM; STEM-CELLS; THERAPY; CANCER; MICRORNA-155; RESPONSES; EFFECTOR;
D O I
10.1073/pnas.1422916112
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Lymphodepleting regimens are used before adoptive immunotherapy to augment the antitumor efficacy of transferred T cells by removing endogenous homeostatic "cytokine sinks." These conditioning modalities, however, are often associated with severe toxicities. We found that microRNA-155 (miR-155) enabled tumor-specific CD8(+) T cells to mediate profound antitumor responses in lymphoreplete hosts that were not potentiated by immune-ablation. miR-155 enhanced T-cell responsiveness to limited amounts of homeostatic gamma c cytokines, resulting in delayed cellular contraction and sustained cytokine production. miR-155 restrained the expression of the inositol 5-phosphatase Ship1, an inhibitor of the serine-threonine protein kinase Akt, and multiple negative regulators of signal transducer and activator of transcription 5 (Stat5), including suppressor of cytokine signaling 1 (Socs1) and the protein tyrosine phosphatase Ptpn2. Expression of constitutively active Stat5a recapitulated the survival advantages conferred by miR-155, whereas constitutive Akt activation promoted sustained effector functions. Our results indicate that overexpression of miR-155 in tumor-specific T cells can be used to increase the effectiveness of adoptive immunotherapies in a cell-intrinsic manner without the need for life-threatening, lymphodepleting maneuvers.
引用
收藏
页码:476 / 481
页数:6
相关论文
共 50 条
  • [21] CD8+ T-cell priming regulated by cytokines of the innate immune system
    Stäger, S
    Kaye, PM
    TRENDS IN MOLECULAR MEDICINE, 2004, 10 (08) : 366 - 371
  • [22] Anti-VEGF Treatment Enhances CD8+ T-cell Antitumor Activity by Amplifying Hypoxia
    de Almeida, Patricia E.
    Mak, Judy
    Hernandez, Genevive
    Jesudason, Rajiv
    Herault, Aurelie
    Javinal, Vincent
    Borneo, Jovencio
    Kim, Jeong M.
    Walsh, Kevin B.
    CANCER IMMUNOLOGY RESEARCH, 2020, 8 (06) : 806 - 818
  • [23] Blocking TIGIT/CD155 signalling reverses CD8+ T cell exhaustion and enhances the antitumor activity in cervical cancer
    Liu, Lu
    Wang, Aihong
    Liu, Xiaoli
    Han, Sai
    Sun, Yu
    Zhang, Junhua
    Guo, Lingyu
    Zhang, Youzhong
    JOURNAL OF TRANSLATIONAL MEDICINE, 2022, 20 (01)
  • [24] Blocking TIGIT/CD155 signalling reverses CD8+ T cell exhaustion and enhances the antitumor activity in cervical cancer
    Lu Liu
    Aihong Wang
    Xiaoli Liu
    Sai Han
    Yu Sun
    Junhua Zhang
    Lingyu Guo
    Youzhong Zhang
    Journal of Translational Medicine, 20
  • [25] CD226 Throttles up CD8+ T Cell Antitumor Activity
    Philip, Mary
    IMMUNITY, 2020, 53 (04) : 704 - 706
  • [26] Intratumoral CD8+ T-cell Apoptosis Is a Major Component of T-cell Dysfunction and Impedes Antitumor Immunity
    Horton, Brendan L.
    Williams, Jason B.
    Cabanov, Alexandra
    Spranger, Stefani
    Gajewski, Thomas F.
    CANCER IMMUNOLOGY RESEARCH, 2018, 6 (01) : 14 - 24
  • [27] Enhancing the efficacy of T cell-based immunotherapies using miR-155 engineered tumor-specific CD8+T cells
    Ji, Yun
    Hocker, James
    Hu, Jinhui
    Gautam, Sanjivan
    Lacey, Neal
    Gattinoni, Luca
    CANCER IMMUNOLOGY RESEARCH, 2017, 5 (03)
  • [28] CD96 Is an Immune Checkpoint That Regulates CD8+ T-cell Antitumor Function
    Mittal, Deepak
    Lepletier, Ailin
    Madore, Jason
    Aguilera, Amelia Roman
    Stannard, Kimberley
    Blake, Stephen J.
    Whitehall, Vicki L. J.
    Liu, Cheng
    Bettington, Mark L.
    Takeda, Kazuyoshi
    Long, Georgina V.
    Scolyer, Richard A.
    Lan, Ruth
    Siemers, Nathan
    Korman, Alan
    Teng, Michele W. L.
    Johnston, Robert J.
    Dougall, William C.
    Smyth, Mark J.
    CANCER IMMUNOLOGY RESEARCH, 2019, 7 (04) : 559 - 571
  • [29] Development of a new non-human primate model to assess CD8+ T cell responses: CD8+ cell depletion of thymectomized rhesus macaques leads to systemic CD8+ naive T-CELL deficiency and altered CD8+ T-CELL responsiveness to de novo challenge
    Lum, Richard
    Rolf, Thomas A.
    Walker, Joshua M.
    Legasse, Alfred
    Axthelm, Michael K.
    Piatak, Michael, Jr.
    Lifson, Jeffrey D.
    Schmitz, Joern E.
    Price, David A.
    Douek, Daniel C.
    Picker, Louis J.
    JOURNAL OF MEDICAL PRIMATOLOGY, 2007, 36 (4-5) : 295 - 295
  • [30] Modeling the CD8+ T effector to memory transition in adoptive T-cell antitumor immunotherapy
    Rolle, Cleo E.
    Carrio, Roberto
    Malek, Thomas R.
    CANCER RESEARCH, 2008, 68 (08) : 2984 - 2992